Cellular and Molecular Aspects of Myeloproliferative Neoplasms - Part B

Lorenzo Galluzzi is Assistant Professor of Cell Biology in Radiation Oncology at the Department of Radiation Oncology of the Weill Cornell Medical College, Honorary Assistant Professor Adjunct with the Department of Dermatology of the Yale School of Medicine, Honorary Associate Professor with the Faculty of Medicine of the University of Paris, and Faculty Member with the Graduate School of Biomedical Sciences and Biotechnology of the University of Ferrara, the Graduate School of Pharmacological Sciences of the University of Padova, and the Graduate School of Network Oncology and Precision Medicine of the University of Rome “La Sapienza”. Moreover, he is Associate Director of the European Academy for Tumor Immunology and Founding Member of the European Research Institute for Integrated Cellular Pathology.Galluzzi is best known for major experimental and conceptual contributions to the fields of cell death, autophagy, tumor metabolism and tumor immunology. He has published over 450 articles in international peer-reviewed journals and is the Editor-in-Chief of four journals:OncoImmunology (which he co-founded in 2011), International Review of Cell and Molecular Biology, Methods in Cell biology, and Molecular and Cellular Oncology (which he co-founded in 2013). Additionally, he serves as Founding Editor for Microbial Cell and Cell Stress, and Associate Editor for Cell Death and Disease, Pharmacological Research and iScience. Niccolo Bartalucci practices in Florence, Italy. Dr. Bartalucci is highly rated in 6 conditions, according to our data. His top areas of expertise are Essential Thrombocythemia, Myelofibrosis, Polycythemia Vera, and Splenomegaly. His clinical research consists of co-authoring 34 peer reviewed articles in the past 15 years.

• PrefaceLorenzo Galluzzi and Niccolò Bartalucci1. The roles of sex and genetics in the MPNAlison R. Moliterno and Evan M. Braunstein2. Transcriptional configurations of myeloproliferative neoplasmsFiorella Schischlik3. Therapeutic targets in MPN and related inhibitorsGabriel Levy, Cristina Mambet, Christian Pecquet, Sarah Bailly, Violaine Havelange, Carmen C. Diaconu and Stefan N. Constantinescu4. Mutational landscape of blast phase myeloproliferative neoplasms (MPN-BP) and antecedent MPNSergiu Pasca, Helen T. Chifotides, Srdan Verstovsek and Prithviraj Bose5. Lessons from mouse models of MPNCamelia Benlabiod, Tracy Dagher, Caroline Marty and Jean-Luc Villeval6. Lab tests for MPNAlice Moncada and Alessandro Pancrazzi